SunTrust Begins Coverage on Alexion Pharmaceuticals (ALXN)
Equities researchers at SunTrust began coverage on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research report issued on Thursday. The firm set a “buy” rating and a $229.00 price target on the stock. SunTrust’s price target would indicate a potential upside of 38.25% from the stock’s previous close.
In other Alexion Pharmaceuticals news, CEO Leonard Bell sold 5,912 shares of Alexion Pharmaceuticals stock in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $169.17, for a total value of $1,000,133.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 2.54% on Thursday, hitting $165.64. The stock had a trading volume of 938,045 shares. Alexion Pharmaceuticals has a 1-year low of $100.89 and a 1-year high of $185.43. The stock has a 50-day moving average of $164.8 and a 200-day moving average of $162.. The company has a market cap of $32.766 billion and a P/E ratio of 85.19.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings data on Thursday, July 24th. The company reported $1.12 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.07 by $0.05. The company had revenue of $512.50 million for the quarter, compared to the consensus estimate of $509.54 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The company’s quarterly revenue was up 38.5% on a year-over-year basis. On average, analysts predict that Alexion Pharmaceuticals will post $5.01 earnings per share for the current fiscal year.
ALXN has been the subject of a number of other recent research reports. Analysts at Credit Suisse initiated coverage on shares of Alexion Pharmaceuticals in a research note on Thursday. They set a “neutral” rating on the stock. Separately, analysts at Nomura reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $224.00 price target on the stock, up previously from $222.00. Finally, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $222.00 price target on the stock, up previously from $220.00. Five investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $186.13.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.